BACKGROUND: Venous thrombus resolution sets up an early intense inflammatory reaction, from which vein wall damage results. Tissue response to injury includes matrix metalloproteinase (MMP) activation and extracellular matrix protein turnover. This study sought to determine the effect of exogenous MMP inhibition and its potential attenuation of early vein wall injury. METHODS: Rats received treatment beginning 24 hr after a stasis venous thrombosis by near occlusive ligation and until harvest at day 7. Three groups were evaluated: (1) vehicle saline controls (NaCl), (2) low molecular weight heparin (LMWH; Lovenox, 3 mg/kg daily SQ), and (3) doxycycline (DOXY, 30 mg/kg daily PO). Thrombus size (mg/mm), levels of tumor necrosis factor alpha (TNF alpha) and D-dimer by colorimetric assay, and monocytes counts by immunohistochemistry were assessed. Vein wall assessment included stiffness by tensiometry, interleukin 1beta (IL-1 beta protein levels by enzyme-linked immunosorbent assay, MMP2 and -9 by zymography, and histological analysis of intimal thickness (IT). Comparisons were by t-test to control. p < 0.05 was considered significant. RESULTS: Thrombus sizes were similar at days 2 and 7 for all three groups, while thrombus TNFalpha was increased in 2-day LMWH- and DOXY-treated groups (NaCl = 1.0 +/- 0.8, LWMH = 9 +/- 3, DOXY = 27 +/- 5 pg/mg protein, n = 6-8, p < 0.05) and at 7 days in the DOXY group (NaCl = 3.0 +/- 2.5, DOXY = 23 +/- 4.2 pg/mg protein, n = 5, p < 0.05). Vein wall stiffness at 7 days was less with LMWH treatment, but not with DOXY, compared to controls (NaCl = 0.33 +/- 0.05, LMWH = 0.17 +/- 0.03, DOXY = 0.43 +/- 0.09 N/mm, n = 5-7, p < 0.05). Vessel-wall IL-1 beta was reduced only in the DOXY group at 7 days (NaCl = 26 +/- 3, LMWH = 38 +/- 17, DOXY = 6 +/- 3 pg/mg protein, n = 4-6, p < 0.05), as was the IT score versus controls (NaCl = 2.2 +/- 0.6, LMWH =1.7 +/- 0.3, DOXY = 0.8 +/- 0.20, n = 4-6, p < 0.05). Zymographic MMP9 activity was significantly reduced at 2 days in the LMWH and DOXY groups (NaCl = 85 +/- 24, LMWH = 23 +/- 7( *), DOXY = 13 +/- 5 U/mg protein, n = 6-8, p < 0.05). MMP2 zymographic activity, thrombus monocyte cell counts, and D-dimer activity were not significantly different across groups. CONCLUSION: Treatment with LMWH or DOXY did not alter the size of deep vein thrombosis, mildly altered thrombus composition, and differentially affected vein wall injury, despite similar reductions in early MMP9 activity. Whether exogenous MMP inhibition affects long-term vein wall fibrosis will require further study. Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
BACKGROUND:Venous thrombus resolution sets up an early intense inflammatory reaction, from which veinwall damage results. Tissue response to injury includes matrix metalloproteinase (MMP) activation and extracellular matrix protein turnover. This study sought to determine the effect of exogenous MMP inhibition and its potential attenuation of early vein wall injury. METHODS:Rats received treatment beginning 24 hr after a stasis venous thrombosis by near occlusive ligation and until harvest at day 7. Three groups were evaluated: (1) vehicle saline controls (NaCl), (2) low molecular weight heparin (LMWH; Lovenox, 3 mg/kg daily SQ), and (3) doxycycline (DOXY, 30 mg/kg daily PO). Thrombus size (mg/mm), levels of tumor necrosis factor alpha (TNF alpha) and D-dimer by colorimetric assay, and monocytes counts by immunohistochemistry were assessed. Veinwall assessment included stiffness by tensiometry, interleukin 1beta (IL-1 beta protein levels by enzyme-linked immunosorbent assay, MMP2 and -9 by zymography, and histological analysis of intimal thickness (IT). Comparisons were by t-test to control. p < 0.05 was considered significant. RESULTS:Thrombus sizes were similar at days 2 and 7 for all three groups, while thrombusTNFalpha was increased in 2-day LMWH- and DOXY-treated groups (NaCl = 1.0 +/- 0.8, LWMH = 9 +/- 3, DOXY = 27 +/- 5 pg/mg protein, n = 6-8, p < 0.05) and at 7 days in the DOXY group (NaCl = 3.0 +/- 2.5, DOXY = 23 +/- 4.2 pg/mg protein, n = 5, p < 0.05). Veinwall stiffness at 7 days was less with LMWH treatment, but not with DOXY, compared to controls (NaCl = 0.33 +/- 0.05, LMWH = 0.17 +/- 0.03, DOXY = 0.43 +/- 0.09 N/mm, n = 5-7, p < 0.05). Vessel-wallIL-1 beta was reduced only in the DOXY group at 7 days (NaCl = 26 +/- 3, LMWH = 38 +/- 17, DOXY = 6 +/- 3 pg/mg protein, n = 4-6, p < 0.05), as was the IT score versus controls (NaCl = 2.2 +/- 0.6, LMWH =1.7 +/- 0.3, DOXY = 0.8 +/- 0.20, n = 4-6, p < 0.05). Zymographic MMP9 activity was significantly reduced at 2 days in the LMWH and DOXY groups (NaCl = 85 +/- 24, LMWH = 23 +/- 7( *), DOXY = 13 +/- 5 U/mg protein, n = 6-8, p < 0.05). MMP2 zymographic activity, thrombus monocyte cell counts, and D-dimer activity were not significantly different across groups. CONCLUSION: Treatment with LMWH or DOXY did not alter the size of deep vein thrombosis, mildly altered thrombus composition, and differentially affected vein wall injury, despite similar reductions in early MMP9 activity. Whether exogenous MMP inhibition affects long-term veinwallfibrosis will require further study. Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
Authors: A Solomon; M Rosenblatt; D Q Li; Z Liu; D Monroy; Z Ji; B L Lokeshwar; S C Pflugfelder Journal: Invest Ophthalmol Vis Sci Date: 2000-08 Impact factor: 4.799
Authors: S W Galt; S Lindemann; D Medd; L L Allen; L W Kraiss; E S Harris; S M Prescott; T M McIntyre; A S Weyrich; G A Zimmerman Journal: Circ Res Date: 2001-09-14 Impact factor: 17.367
Authors: R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson Journal: J Clin Invest Date: 2000-06 Impact factor: 14.808
Authors: Kenneth J Woodside; Mingdao Hu; Ann Burke; Maki Murakami; Lori L Pounds; Lois A Killewich; John A Daller; Glenn C Hunter Journal: J Vasc Surg Date: 2003-07 Impact factor: 4.268
Authors: J Gabre; C Chabasse; C Cao; S Mukhopadhyay; S Siefert; Y Bi; S Netzel-Arnett; R Sarkar; L Zhang Journal: J Thromb Haemost Date: 2014-01 Impact factor: 5.824
Authors: Jose A Diaz; Nicole E Ballard-Lipka; Diana M Farris; Angela E Hawley; Shirley K Wrobleski; Daniel D Myers; Peter K Henke; Daniel A Lawrence; Thomas W Wakefield Journal: J Vasc Surg Date: 2011-11-25 Impact factor: 4.268
Authors: S A Siefert; C Chabasse; S Mukhopadhyay; M H Hoofnagle; D K Strickland; R Sarkar; T M Antalis Journal: J Thromb Haemost Date: 2014-09-30 Impact factor: 5.824
Authors: Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2013-03-13 Impact factor: 4.268
Authors: Christine Chabasse; Suzanne A Siefert; Mohammed Chaudry; Mark H Hoofnagle; Brajesh K Lal; Rajabrata Sarkar Journal: J Vasc Surg Venous Lymphat Disord Date: 2014-05-10
Authors: Joe F Baldwin; Vikram Sood; Megan A Elfline; Cathy E Luke; Nicholas A Dewyer; Jose A Diaz; Dan D Myers; Thomas Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2012-07-15 Impact factor: 4.268
Authors: Kristopher B Deatrick; Andrea Obi; Catherine E Luke; Megan A Elfline; Vikram Sood; Gilbert R Upchurch; Farouc Jaffer; Thomas W Wakefield; Peter K Henke Journal: Thromb Res Date: 2013-08-24 Impact factor: 3.944
Authors: Khanh P Nguyen; Kirk C McGilvray; Christian M Puttlitz; Subhradip Mukhopadhyay; Christine Chabasse; Rajabrata Sarkar Journal: PLoS One Date: 2015-09-25 Impact factor: 3.240